Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Please be advised there have been no changes to the Aspire equity line and it remains available for the Company to use as appropriate."

No one suggested that there had been any changes to the Aspire equity line, at least I certainly didn't. And to say that "it remains available for the Company to use as appropriate" doesn't fully answer any of the questions that were asked.

I'd say that it was a half baked response (it suggests that all of the remaining Aspire line is immediately available....is it?) but I suspect that that was partly due to the way the question was asked (we haven't been told). I'm reminded of the failure of the CEO to specify the price standard that couldn't be met at uplist time. He slid right past it.

I had a couple pretty specific questions that were ignored, but here's the gist of today's FUDDY question. Maybe someone who can grasp it can forward it along:
Is the fact that the market value of the holdings of IPIX's non-affiliated shareholders is less than $75M, which has the potential to limit access to the full value of the S-3 registration and the entire balance of the Aspire line, having any bearing on managements operating decisions or isn't it? Are any trials being delayed for financial reasons attributable to the limitations described in the S-3 Registration Statement's Instruction 1.B.6 (not counting P3 B ABSSSI, of course)?



Maybe YOU can answer a question for me. What trials are on IPIX's current agenda....as in What's next? I haven't been paying as much attention as I should.